# Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma

> **NCT04705519** · PHASE2 · COMPLETED · sponsor: **Peking University** · enrollment: 79 (actual)

## Conditions studied

- Neuroendocrine Carcinoma

## Interventions

- **DRUG:** Nab-paclitaxel Combined With Bevacizumab

## Key facts

- **NCT ID:** NCT04705519
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-05
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2025-03-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04705519

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04705519, "Nab-paclitaxel Combined with Bevacizumab in the Treatment of Metastatic Extrapulmonary Neuroendocrine Carcinoma". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04705519. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*